Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.66 |
| ▸ | DHFR | P00374 | 1/20 | 0.53 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | ACP1 | P24666 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5402069 | 0.83 | MEN1 (0.54) | HRH4EGLN1MEN1KMT2ANPY5R | |
| SCHEMBL5404396 | 0.81 | MEN1 (0.54) | HRH4EGLN1MEN1KMT2ANPY5R | |
| SCHEMBL5406200 | 0.81 | MEN1 (0.54) | HRH4EGLN1MEN1KMT2ANPY5R | |
| SCHEMBL5395227 | 0.80 | MEN1 (0.56) | HRH4EGLN1MEN1KMT2ANPY5R | |
| SCHEMBL5420536 | 0.80 | MEN1 (0.56) | HRH4EGLN1MEN1KMT2ANPY5R | |
| SCHEMBL5401967 | 0.79 | KMT2A (0.52) | HRH4EGLN1MEN1KMT2AMAPT | |
| SCHEMBL7147827 | 0.79 | MEN1 (0.49) | HRH4EGLN1MEN1KMT2ANPY5R | |
| SCHEMBL5408413 | 0.79 | MEN1 (0.46) | HRH4EGLN1MEN1KMT2ANPY5R | |
| SCHEMBL5406793 | 0.78 | KDM4E (0.54) | HRH4MEN1KMT2AMAPTNPY5R | |
| SCHEMBL5412855 | 0.78 | CYP1A2 (0.53) | HRH4EGLN1MEN1KMT2ANPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265125-B2 | Neuropeptide Y antagonists | HOFFMANN-LA ROCHE INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-20050176698-A1 | Neuropeptide Y antagonists | BREU VOLKER (DE) | 2005-08-11 | — | — | US | disclosed |
| US-6900226-B2 | Neuropeptide Y antagonists | HOFFMAN-LA ROCHE INC. (US) | 2005-05-31 | — | — | US | disclosed |
| US-20020052356-A1 | Neuropeptide Y antagonists | F.HOFFMANN-LA ROCHE AG (CH) | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176698-A1 | Neuropeptide Y antagonists | NPY5R, NPY4R, NPY2R | HRH4 279/4885DHFR 4641/4885EGLN1 1248/4885 |
| US-20020052356-A1 | Neuropeptide Y antagonists | NPY5R, NPY4R, NPY2R | HRH4 279/4885DHFR 4641/4885EGLN1 1248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.